The latest study on the GSK vaccine efforts showed surprisingly good progress when using an adjuvant, an additive that makes it possible to use less vaccine. Also, the vaccine was able to produce an immune response to multiple strains of the virus.
"In fact, the dose needed for a good response was almost four times lower than that used normally in influenza vaccines, meaning limited supplies would stretch to more people.
The researchers also found the vaccine produced immune responses against H5N1 subtypes from Vietnam and Indonesia.
Potentially, the vaccine, made by GSK, could be produced in advance before it was known what strain was causing a pandemic, they said. "
http://news.bbc.co.uk/1/hi/health/6949465.stm
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment